Tag: Sacituzumab govitecan

Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026

Gilead Accelerate Its Oncology ADC Pipeline by Acquiring Tubulis for $5B

TROP-2 and the Promise and Peril of High-Affinity in ADCs -- Over the last decades, Antibody–drug conjugates (ADCs) have emerged as a transformative class of cancer therapeutics, offering the promise of targeted cytotoxicity with the precision of monoclonal antibodies.* To fulfill this promise, the ideal ADC includes an antibody that is specific for binding to the target antigen, has high binding affinity for that target, and, at the same time, has low immunogenicity.  In addition, the antibody should have a long plasma half-life and rapid internalization.

Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of Care in First-line PD-L1+ mTNBC

SABCS 2025: Combination of Invikafusp Alfa and Sacituzumab Govitecan Demonstrates Positive Results in Ongoing Study

ESMO 2025: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care

The combination of sacituzumab govitecan (Trodelvy®; Gilead Sciences; See ADC Drugmap)* + pembrolizumab (Keytruda®; Merck & Co/MSD) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care (SoC) pembrolizumab plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC).

A first patients has been dosed in the WIN-B study (NCT06612203)*, a Phase 1b/2, multi-center investigator-initiated trial evaluating the safety and preliminary efficacy of...

VBC103 (VelaVigo Cayman) is a bispecific ADC that selectively targets both TROP-2 and Nectin4, which are highly co-expressed in urothelial carcinoma, TNBC, and other tumors.

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992 (also known as BSI-992), to conduct a...